Skip to main content

Table 1 Demographics of the study population

From: Clopidogrel versus ticagrelor in the treatment of Chinese patients undergoing percutaneous coronary intervention: effects on platelet function assessed by platelet function tests and mean platelet volume

Variables Aspirin + clopidogrel group
(n = 46)
Aspirin + ticagrelor group
(n = 66)
P
Age, yrs. 58.1 ± 9.1 56.3 ± 11.6 0.401
Male, n (%) 36(78.3) 55(83.3) 0.499
BMI, kg/m2 25.9 ± 3.3 25.9 ± 3.2 0.963
LVEF, % 63.0(60.0, 66.0) 60.0(52.8, 65.0) < 0.001
Risk factors
 Hypertension, n (%) 33(71.7) 31(47.0) 0.009
 Diabetes, n (%) 9(19.6) 26(39.4) 0.026
 Hyperlipidemia, n (%) 43(93.5) 58(89.2) 0.441
Past history
 Previous PCI, n (%) 9(19.6) 28(42.4) 0.011
 Previous MI, n (%) 17(37.0) 56(84.8) < 0.001
 Previous stroke, n (%) 10(22.2) 4(6.1) 0.012
Medications
 Statins, n (%) 46(100.0) 66(100.0) 1.000
 ACEI, n (%) 11(24.4) 29(46.0) 0.022
 ARB, n (%) 8(18.2) 7(11.1) 0.300
 β-blocker, n (%) 38(84.4) 60(93.8) 0.112
Laboratory
 Hemoglobin, g/L 147.7 ± 14.0 143.5 ± 12.4 0.095
 LDL-C, mmol/L 2.0(1.7, 2.8) 2.2(1.5, 2.7) 0.708
 HsCRP, mg/L 1.1(0.5, 3.0) 2.6(1.2, 7.2) 0.006
 AST, U/L 22.0(19.0, 27.5) 27.0(20.0, 85.0) 0.007
 ALT, U/L 27.0(17.0, 39.2) 32.5(22.8, 52.5) 0.022
 Platelet, 109 cells/L 223.1 ± 60.2 244.7 ± 69.7 0.091
 MPV, fL 11.4 ± 1.4 10.2 ± 0.9 < 0.001
  1. Values are mean ± SD if the distribution is normal; median (interquartile range) if skewed; number, n (proportions, %) for categorical variables
  2. ACEI Angiotensin converting enzyme inhibitor, ALT Alanine transaminase, AST Aspartate transaminase, ARB Angiotensin receptor blocker, BMI Body mass index, CABG Coronary artery bypass graft, hsCRP highly sensitive C-reactive protein, LDL-C Low-density lipoprotein cholesterol, LVEF Left ventricular ejection fraction, MI Myocardial infarction, MPV Mean platelet volume, PCI Percutaneous coronary intervention